Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Videos|June 11, 2021
CDMOs: Embracing Change and a Look Toward the Future
Author(s)AMRI
John Ratliff entered the contract research, development and manufacturing (CDMO) industry at the end of 2019, just months before the COVID-19 pandemic emerged. As a veteran of the information technology and clinical research (CRO) industries, he is accustomed to leading through dramatic change. Here, John discusses his approach to leading through periods of uncertainty and shares how AMRI has embraced change, staying relevant to its customers while preparing to celebrate its 30-year anniversary. Topics of discussion include:
· How the COVID-19 pandemic meets an industry in the midst of change
· Leading through transformational change
· Industry and AMRI’s evolution over the course of 30 years
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.